In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:
- Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
- Evaluating the future impact of key items when reviewing a biotech IP portfolio
- Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
- Valuation methodologies used for early-stage vs. late-stage products
Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.
Related Insights
June 13, 2025
Foley Viewpoints
Eighth Circuit Affirms Summary Judgment to Insurer in Dispute with Construction Project Owner Over Lost Rental Income
On Monday, June 9, 2025, the Eighth Circuit Court of Appeals ruled that a Missouri real estate developer could not recover insurance…
June 13, 2025
Foley Viewpoints
Your Company Received an ICE Notice of Inspection — Now What?
“Worksite enforcement operations are going to massively expand,” according to a June 12, 2025, interview[1] with Border Czar Tom Homan….
June 13, 2025
Energy Current
Key Provisions of the One Big Beautiful Bill (H.R.1) Related to Foreign Ownership and Foreign Supply (FEOC)
Applicable Limitations on Tax Credits under Sections 48E, 45Y, and 45X: The below summary describes provisions in the One Big Beautiful…